← Search & browse all drugs
CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › ANTIARRHYTHMICS, CLASS I AND III › Antiarrhythmics, class III
bunaftine
C01BD03
Forms & Strengths
- Oral tablets 50 mg
- Oral tablets 100 mg
- Intravenous injection 10 mg/mL
Adult Dosing
- Supraventricular and ventricular arrhythmias: Oral 50 to 100 mg three times daily
- Intravenous loading dose: 1 to 2 mg/kg administered slowly over 5 to 10 minutes
- Maintenance infusion: 1 to 2 mg/min titrated to clinical response
Pediatric Dosing
- Safety and efficacy in pediatric patients not established
- Use in children is off-label and requires specialist consultation
Indications
- Treatment of supraventricular arrhythmias
- Management of symptomatic ventricular arrhythmias
Mechanism of Action
- Class III antiarrhythmic agent
- Prolonges cardiac action potential and effective refractory period
- Inhibits potassium channels in cardiac muscle fibers
Contraindications
- Hypersensitivity to bunaftine
- Third-degree atrioventricular block without a functioning pacemaker
- Severe bradycardia or cardiogenic shock
- Prolonged QT interval syndrome
Adverse Reactions
- Proarrhythmia including torsades de pointes
- Bradycardia and hypotension
- Dizziness and headache
- Nausea and gastrointestinal distress
Drug Interactions
- Increased risk of QT prolongation and arrhythmias with other Class IA or Class III antiarrhythmics
- Enhanced bradycardia when combined with beta-blockers or non-dihydropyridine calcium channel blockers
- Potential electrolyte disturbances with diuretics increasing proarrhythmic risk
Curated Content: Needs Vetting Before Put to Clinical Use